Safety and Efficacy of Second-Line TKI Plus Anti-PD1 Following Targeted Therapy in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study

Wang, Jun; Liu, Ruiqi; Wei, Wensu; Liu, Yang; Zhang, Zhiling; Guo, Shengjie; Han, Hui; Zhou, Fangjian; He, Liru; Dong, Pei

doi:10.2139/ssrn.4112146

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pathogenesis of clear cell carcinoma varies depending on the primary site, but some shared molecular features have been identified. For example, Von Hippel-Lindau (VHL) gene alterations are frequently observed in renal clear cell carcinoma, leading to increased hypoxia-inducible factor (HIF) activity and subsequent angiogenesis, cell proliferation, and tumor growth [3].…”

Section: Discussionmentioning

confidence: 99%

Metastatic Clear Cell Carcinoma of Unknown Primary Origin in an Elderly Female Patient With Paraneoplastic Hypercalcemia

Al Omour,

Aiman,

Venkatesvaran

et al. 2024

Cureus

View full text Add to dashboard Cite

Metastatic clear cell carcinoma (mCCC) is a rare histological subtype of cancer with ovarian and renal origins most common primary sites. Cancer of unknown primary origin (CUP) is a rare type of cancer in the United States and the most common histologic subtypes are adenocarcinoma, squamous cell cancer, and neuroendocrine cancer. We are presenting a rare case of an 86-year-old female patient with mCCC of unknown origin, biopsy and staining showed renal and ovarian in the differential of primary cancer type. However, the patient did not survive the aggressive nature of mCCC and was unable to get any trials of chemotherapy. Primary sites of adenocarcinoma of unknown origin are most common in the breast, lung, pancreas, prostate, colon, and liver. In most cases, empiric chemotherapy with platinum-based agents is the standard of care but needs more data to manage CUP, making it difficult to identify the primary site.

show abstract

Section: Discussionmentioning

confidence: 99%

Metastatic Clear Cell Carcinoma of Unknown Primary Origin in an Elderly Female Patient With Paraneoplastic Hypercalcemia

Al Omour,

Aiman,

Venkatesvaran

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Immunotherapies, including immune checkpoint inhibitors like nivolumab and pembrolizumab, seek to mobilize the immune system against cancer cells by disrupting evasion mechanisms . Molecularly targeted agents, such as sunitinib and pazopanib, leverage specific genetic alterations to inhibit angiogenesis and tumor growth pathways [23,30,38,[42][43][44][45][46][47][48]. These recent treatment options can complement the treatment landscape of RCC using complementary molecular mechanism based on the studies of biology, pathology, and genomics of renal carcinoma and can ultimately start the diamond age of precision treatment where RCC medicine can be tailored to specific patients based on biological and pathological circumstances [17].…”

Section: Introductionmentioning

confidence: 99%

Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review

Sofia,

Zhou,

Shahriyari

2023

Bioengineering

View full text Add to dashboard Cite

This review explores the multifaceted landscape of renal cell carcinoma (RCC) by delving into both mechanistic and machine learning models. While machine learning models leverage patients’ gene expression and clinical data through a variety of techniques to predict patients’ outcomes, mechanistic models focus on investigating cells’ and molecules’ interactions within RCC tumors. These interactions are notably centered around immune cells, cytokines, tumor cells, and the development of lung metastases. The insights gained from both machine learning and mechanistic models encompass critical aspects such as signature gene identification, sensitive interactions in the tumors’ microenvironments, metastasis development in other organs, and the assessment of survival probabilities. By reviewing the models of RCC, this study aims to shed light on opportunities for the integration of machine learning and mechanistic modeling approaches for treatment optimization and the identification of specific targets, all of which are essential for enhancing patient outcomes.

show abstract

Safety and Efficacy of Second-Line TKI Plus Anti-PD1 Following Targeted Therapy in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study

Cited by 2 publications

References 24 publications

Metastatic Clear Cell Carcinoma of Unknown Primary Origin in an Elderly Female Patient With Paraneoplastic Hypercalcemia

Metastatic Clear Cell Carcinoma of Unknown Primary Origin in an Elderly Female Patient With Paraneoplastic Hypercalcemia

Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review

Contact Info

Product

Resources

About